News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma evaluates commercial potential of myocardial infarction indication

October 14, 2013

PledPharma AB
Company Announcement

PledPharma evaluates commercial potential of myocardial infarction indication

Stockholm, 2013-10-14 08:10 CEST (GLOBE NEWSWIRE) -- 

The results from the MANAMI study, which was presented this morning, show that
PLED substance was well tolerated by patients in the study and can be given to
patients suffering from serious heart disease without any side-effects. Despite
the study's limited size, a tendency towards clinical effect was seen. 

In the MANAMI study, patients were pretreated with PLED- substance before PCI
(percutaneous coronary intervention) in acute myocardial infarction. The
results of the study strengthen the PLED- platform and further reduces the

In addition to the results in the MANAMI study, promising results have
previously also been shown in the oncology study MANFOL. These studies are
based on the same substance platform but in two independent diseases. 

Rapid restoration of the blood flow (reperfusion) to the heart muscle by PCI is
an effective treatment in acute myocardial infarction but reperfusion injury
may lead to weakening of the heart’s ability with increased risk of morbidity
and mortality. The medical need is thus great since there currently are no
drugs that can limit the reperfusion injury. 

"MANAMI is a small study within a very large and difficult therapeutic area. 
As PledPharma has previously communicated, we have chosen to focus our
resources on the oncology project. However, based on these results we will now
evaluate the commercial potential of the myocardial infarction indication”,
says CEO Jacques Näsström. 

For further information please contact:

Jacques Näsström, CEO PledPharma, phone +46 73 713 09 79

See also, complementing press release “PledPharma reports results from the
MANAMI-study in patients with acute myocardial infarction” 

About PledPharma
PledPharma is a Swedish specialty pharma company that develops PledOx® for
prevention of severe chemotherapy-induced side effects in cancer patients. Due
to these side effects optimal treatment cannot be carried out. The current
market for supportive cancer care is some SEK 72 billion. PledOx protects
normal cells against oxidative stress. It belongs to a group of compounds named
lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese
SuperOxide Distmutase (MnSOD) – the most important endogenous cellular
protectant against devastating oxidative stress. Oxidative stress is a
condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of
chemotherapy treatment. The company is also evaluating opportunities of using
PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ
OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For
further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10